Holen Sie sich die Stockscreener-App
1.60
4.76%
-0.08
Handel nachbörslich:
1.60
Schlusskurs vom Vortag:
$1.68
Offen:
$1.69
24-Stunden-Volumen:
999.89K
Relative Volume:
0.82
Marktkapitalisierung:
$124.16M
Einnahmen:
$257.24M
Nettoeinkommen (Verlust:
$-237.89M
KGV:
-0.6154
EPS:
-2.6
Netto-Cashflow:
$-175.17M
1W Leistung:
+0.00%
1M Leistung:
-2.44%
6M Leistung:
+45.45%
1J Leistung:
+121.30%
1-Tages-Spanne:
$1.57
$1.72
1-Wochen-Bereich:
$1.57
$1.805
52-Wochen-Spanne:
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
Firmenname
Coherus Oncology Inc
Sektor
Branche
Telefon
(650) 649-3530
Adresse
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Vergleichen Sie CHRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.60 | 195.26M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Hochstufung | Maxim Group | Hold → Buy |
| 2024-08-16 | Herabstufung | UBS | Buy → Neutral |
| 2023-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2023-07-24 | Eingeleitet | Citigroup | Buy |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2023-03-28 | Hochstufung | UBS | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Neutral |
| 2022-03-07 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Eingeleitet | BofA Securities | Neutral |
| 2020-04-17 | Eingeleitet | SunTrust | Buy |
| 2019-08-13 | Eingeleitet | Mizuho | Buy |
| 2019-08-02 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-02 | Bestätigt | Maxim Group | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-09 | Bestätigt | Maxim Group | Buy |
| 2017-08-08 | Bestätigt | JP Morgan | Overweight |
| 2017-06-13 | Bestätigt | Maxim Group | Buy |
| 2017-05-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2016-10-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-09-07 | Eingeleitet | Maxim Group | Buy |
| 2016-07-27 | Eingeleitet | Citigroup | Buy |
| 2016-01-20 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Coherus Oncology Inc Aktie (CHRS) Neueste Nachrichten
3 Penny Stocks With Market Caps Over $80M To Consider - Yahoo Finance
Coherus Oncology's (NASDAQ:CHRS) investors will be pleased with their solid 132% return over the last year - Yahoo Finance
Can Coherus Oncology Inc. (8C5) stock retain market dominanceMarket Activity Report & Long-Term Safe Investment Plans - newser.com
Will Coherus BioSciences Inc. stock recover faster than marketBuy Signal & Breakout Confirmation Trade Signals - newser.com
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Coherus Oncology (NASDAQ: CHRS) schedules Nov. 6 results release and 5 p.m. ET call - Stock Titan
CapEx per share of Coherus Oncology, Inc. – DUS:8C5 - TradingView
Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Coherus Oncology (CHRS) to Release Quarterly Earnings on Wednesday - MarketBeat
How Coherus Oncology Inc. (8C5) stock performs during market turbulenceLayoff News & Scalable Portfolio Growth Methods - newser.com
Despite shrinking by US$22m in the past week, Coherus Oncology (NASDAQ:CHRS) shareholders are still up 122% over 1 year - simplywall.st
Aug Ideas: How Coherus Oncology Inc. (8C5) stock performs during market turbulenceJuly 2025 Retail & Consistent Profit Trading Strategies - Fundação Cultural do Pará
Coherus Oncology (NASDAQ:CHRS) Given "Sell (D)" Rating at Weiss Ratings - MarketBeat
Will Coherus BioSciences Inc. stock deliver better than expected guidanceLayoff News & Real-Time Volume Surge Alerts - newser.com
Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
What analysts say about Coherus Oncology Inc 8C5 stockStock Buy Signals & Maximum Profit Growth - earlytimes.in
Will Coherus Oncology Inc. (8C5) stock benefit from infrastructure billPortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Coherus Oncology to Participate in Upcoming Investor Conferences - The Manila Times
Will Coherus Oncology Inc. (8C5) stock outperform value peersBuy Signal & Community Verified Trade Alerts - newser.com
Lobbying Update: $80,000 of COHERUS BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
What dividend safety rating applies to Coherus Oncology Inc. (8C5) stock2025 Volume Leaders & Expert Curated Trade Ideas - newser.com
Why Coherus Oncology Inc. (8C5) stock is trending on social media2025 Geopolitical Influence & Long Hold Capital Preservation Tips - newser.com
Guidance Update: Will Coherus Oncology Inc. (8C5) stock outperform value peersJuly 2025 Momentum & Long-Term Growth Portfolio Plans - nchmf.gov.vn
Stock Market Recap: Will Coherus Oncology Inc. (8C5) stock outperform value peersJuly 2025 Trends & Technical Pattern Recognition Alerts - Trung tâm Dự báo KTTV quốc gia
CHRS (Coherus Oncology) EBITDA Margin % : -405.39% (As of Jun. 2025) - GuruFocus
Coherus Oncology, Inc.Common Stock (Nasdaq:CHRS) Stock Quote | Oklahoma City NewsThe Oklahoman - FinancialContent
How Coherus Oncology Inc. (8C5) stock reacts to monetary easing2025 Dividend Review & Real-Time Market Trend Scan - newser.com
Coherus Oncology (NASDAQ:CHRS) Share Price Passes Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
What technical patterns form on Coherus Oncology Inc. (8C5) stock chartsMarket Sentiment Review & Weekly Return Optimization Plans - newser.com
Revenue per share of Coherus Oncology, Inc. – MUN:8C5 - TradingView
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals - inkl
How strong dollar benefits Coherus Oncology Inc. (8C5) stockJuly 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Finanzdaten der Coherus Oncology Inc-Aktie (CHRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):